A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

George A. Fisher,Nehal J. Lakhani,Cathy Eng,J. Randolph Hecht,Johanna C. Bendell,Philip A. Philip,Peter J. O’Dwyer,Benny Johnson,Adel Kardosh,Tina M Ippolito,Yan V. Wang,Balaji Agoram,Jens Peter Volkmer,Roy L. Maute,Isagani Chico,Mark P. Chao,Chris H. Takimoto,Amita Patnaik

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

2020

George A. Fisher
Nehal J. Lakhani
Cathy Eng
J. Randolph Hecht
Johanna C. Bendell
Philip A. Philip
Peter J. O’Dwyer
Benny Johnson
Adel Kardosh
Tina M Ippolito
Yan V. Wang
Balaji Agoram
Jens Peter Volkmer
Roy L. Maute
Isagani Chico
Mark P. Chao
Chris H. Takimoto
Amita Patnaik

114Background: Magrolimab (M, Hu5F9-G4) is an antibody targeting CD47, a macrophage “don’t eat me” signal that demonstrates preclinical synergy with cetuximab (C) in refractory KRAS wild type (KRAS...

Keywords:

solid tumor
Antibody
CD47
Cetuximab
Cancer research
Medicine
Colorectal cancer
Pathology
KRAS
Wild type
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations